DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenue- Hardware' to reach $38.99 million. The estimate indicates a year-over-year change of -32%.
It is projected by analysts that the 'Revenue- Sensor and other' will reach $1.08 billion. The estimate suggests a change of +14.5% year over year.
According to the collective judgment of analysts, 'Revenue- United States' should come in at $809.70 million. The estimate indicates a change of +10.6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- International' will likely reach $311.29 million. The estimate indicates a year-over-year change of +14.3%.
View all Key Company Metrics for DexCom here>>>
Over the past month, DexCom shares have recorded returns of +3.1% versus the Zacks S&P 500 composite's +4.9% change. Based on its Zacks Rank #2 (Buy), DXCM will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Nutrien (NTR) Q2 Earnings Surpass Estimates
Nutrien (NTR) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.4 per share. This compares to earnings of $2.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +10.42%. A quarter ago, it was expected that this producer of potash and other fertilizers would post earnings of $0.33 per share when it actually produced earnings of $0.11, delivering a surprise of -66.67%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Nutrien, which belongs to the Zacks Fertilizers industry, posted revenues of $10.44 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.62%. This compares to year-ago revenues of $10.16 billion. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Nutrien shares have added about 32.1% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for Nutrien? While Nutrien has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Nutrien was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.81 on $5.77 billion in revenues for the coming quarter and $4.00 on $26.89 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Fertilizers is currently in the top 7% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Basic Materials sector, Daqo New Energy (DQ), is yet to report results for the quarter ended June 2025. This solar panel parts maker is expected to post quarterly loss of $1.16 per share in its upcoming report, which represents a year-over-year change of +35.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Daqo New Energy's revenues are expected to be $136.4 million, down 38% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nutrien Ltd. (NTR) : Free Stock Analysis Report DAQO New Energy Corp. (DQ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
UGI (UGI) Reports Q3 Loss, Lags Revenue Estimates
UGI (UGI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +91.67%. A quarter ago, it was expected that this natural gas and electric utilities operator. would post earnings of $1.8 per share when it actually produced earnings of $2.21, delivering a surprise of +22.78%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. UGI, which belongs to the Zacks Utility - Gas Distribution industry, posted revenues of $1.39 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.44%. This compares to year-ago revenues of $1.38 billion. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. UGI shares have added about 28.8% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for UGI? While UGI has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for UGI was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.37 on $1.64 billion in revenues for the coming quarter and $3.13 on $7.81 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Utility - Gas Distribution is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Sempra (SRE), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This natural gas and electricity provider is expected to post quarterly earnings of $0.83 per share in its upcoming report, which represents a year-over-year change of -6.7%. The consensus EPS estimate for the quarter has been revised 8.8% higher over the last 30 days to the current level. Sempra's revenues are expected to be $3.15 billion, up 4.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UGI Corporation (UGI) : Free Stock Analysis Report Sempra Energy (SRE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Staar Surgical (STAA) Reports Q2 Loss, Beats Revenue Estimates
Staar Surgical (STAA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +87.50%. A quarter ago, it was expected that this maker of implantable lenses would post a loss of $0.59 per share when it actually produced a loss of $0.52, delivering a surprise of +11.86%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Staar Surgical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $44.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.63%. This compares to year-ago revenues of $99 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Staar Surgical shares have added about 11.2% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for Staar Surgical? While Staar Surgical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Staar Surgical was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.18 on $87.83 million in revenues for the coming quarter and -$0.78 on $258.21 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Becton Dickinson (BDX), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This medical device manufacturer is expected to post quarterly earnings of $3.42 per share in its upcoming report, which represents a year-over-year change of -2.3%. The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. Becton Dickinson's revenues are expected to be $5.48 billion, up 9.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STAAR Surgical Company (STAA) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
